A classy choice for menopausal women.
Products 전체보기
Enhancing the elegance of 49% rare agarwood with 19 kinds of premium traditional ingredients.
Agarwood (from Indonesia) 49%, Deer antler (from New Zealand) 0.7%, Red ginseng (domestic) 2%, Pine needles (domestic) 4%, Apis honey (domestic) 17%, Pollen (domestic) 1%, Ginger (from Peru) 2%, Angelica (domestic) 2%, Cornus fruit (domestic) 3%, Chinese yam (imported) 3%, Eucommia (domestic) 3%, Schisandra (domestic) 2%, Korean black raspberry (domestic) 2%, Goji berry (domestic) 2%, Dried tangerine peel (domestic) 2%, Licorice (imported) 0.2%, Cinnamon (from Vietnam) 1%, Glycerin 1%, Clove 1%, Menthol 1.1%
Agarwood (from Indonesia) 49%, Deer antler (from New Zealand) 0.7%, Red ginseng (domestic) 2%, Pine needles (domestic) 4%, Apis honey (domestic) 17%, Pollen (domestic) 1%, Ginger (from Peru) 2%, Angelica (domestic) 2%, Cornus fruit (domestic) 3%, Chinese yam (imported) 3%, Eucommia (domestic) 3%, Schisandra (domestic) 2%, Korean black raspberry (domestic) 2%, Goji berry (domestic) 2%, Dried tangerine peel (domestic) 2%, Licorice (imported) 0.2%, Cinnamon (from Vietnam) 1%, Glycerin 1%, Clove 1%, Menthol 1.1%
When your liver needs a break.
Contains Codium ocordol namul
4g * 30 packets
Contains Codium ocordol namul
4g * 30 packets
Papers 전체보기
Brief Summary
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as part of standard practice. Patients meeting the criteria for early Alzheimer's disease will be considered for study participation, with the Investigator taking the additional inclusion/exclusion criteria into consideration. Up to 40 subjects will be enrolled. Subjects participating in the study will be randomized to receive either gummies containing L-Serine or placebo gummies, with the Investigator and study staff blinded to the group assignments.
Detailed Description
L-serine (C3H7NO3; 105.09 g/mol; synonym (S)-2-amino-3-hydroxypropanoic acid) is a naturally-occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs, and meat. Since some L-serine is produced by astrocytes in the brain, it is considered a non-essential amino acid. L-serine is directly involved in the biosynthesis of purines, pyrimidines, and other amino acids. Serine residues are found in most proteins and within proteins function as a site for phosphorylation.
L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320. It is widely sold as a dietary supplement. A pilot study of L-serine supplementation of 14 patients with hereditary sensory neuropathy has been published, and subsequent trial is on-going (ClinicalTrials.gov identifier NCT01733407). The authors did not report adverse effects at doses of 400mg/kg/day, which for an average American of 75.5kg is about 30 grams, the dose which we propose to use in this study.
L-serine will be administered orally through gummies. Each gummy contains 1 g L-serine (treatment) and will be packaged in a foil packet containing 15 pieces to be taken both morning and evening for nine months. The placebo will be a gummy containing no L-serine, packaged and taken in the same manner. In order to assess tolerability in patients, we have designed a 4 week dose ramp-up. We will monitor side-effects and amino acid balances in blood samples in the early Alzheimer's Disease patients during a dose ramp-up period. If a patient cannot tolerate the full dose of gummies, they will remain in the study taking a total of 1 package of gummies split into two time periods within the day. The same ramp-up schedule and procedures will be observed for both placebo and L-serine patients. Patients will be assessed at baseline, 3 months, 6 months, and 9 months.
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as part of standard practice. Patients meeting the criteria for early Alzheimer's disease will be considered for study participation, with the Investigator taking the additional inclusion/exclusion criteria into consideration. Up to 40 subjects will be enrolled. Subjects participating in the study will be randomized to receive either gummies containing L-Serine or placebo gummies, with the Investigator and study staff blinded to the group assignments.
Detailed Description
L-serine (C3H7NO3; 105.09 g/mol; synonym (S)-2-amino-3-hydroxypropanoic acid) is a naturally-occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs, and meat. Since some L-serine is produced by astrocytes in the brain, it is considered a non-essential amino acid. L-serine is directly involved in the biosynthesis of purines, pyrimidines, and other amino acids. Serine residues are found in most proteins and within proteins function as a site for phosphorylation.
L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320. It is widely sold as a dietary supplement. A pilot study of L-serine supplementation of 14 patients with hereditary sensory neuropathy has been published, and subsequent trial is on-going (ClinicalTrials.gov identifier NCT01733407). The authors did not report adverse effects at doses of 400mg/kg/day, which for an average American of 75.5kg is about 30 grams, the dose which we propose to use in this study.
L-serine will be administered orally through gummies. Each gummy contains 1 g L-serine (treatment) and will be packaged in a foil packet containing 15 pieces to be taken both morning and evening for nine months. The placebo will be a gummy containing no L-serine, packaged and taken in the same manner. In order to assess tolerability in patients, we have designed a 4 week dose ramp-up. We will monitor side-effects and amino acid balances in blood samples in the early Alzheimer's Disease patients during a dose ramp-up period. If a patient cannot tolerate the full dose of gummies, they will remain in the study taking a total of 1 package of gummies split into two time periods within the day. The same ramp-up schedule and procedures will be observed for both placebo and L-serine patients. Patients will be assessed at baseline, 3 months, 6 months, and 9 months.
Ginseng, the root of the Panax ginseng, has been a popular and widely-used traditional herbal medicine in Korea, China, and Japan for thousands of years. Now it has become popular as a functional health food and is used globally as a natural medicine. Evidence is accumulating in the literature on the physiological and pharmacological effects of P. ginseng on neurodegenerative diseases. Possible ginseng- or ginsenosides-mediated neuroprotective mechanisms mainly involve maintaining homeostasis, and anti-inflammatory, anti-oxidant, anti-apoptotic, and immune-stimulatory activities. This review considers publications dealing with the various actions of P. ginseng that are indicative of possible neurotherapeutic efficacies in neurodegenerative diseases and neurological disorders such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis and multiple sclerosis.
Whether distinct blood metabolomic profiles can distinguish Parkinson’s disease (PD) patients from healthy controls (HC) is still a matter of debate. Here, we employed ¹H-NMR and UPLC/MS analyses on serum samples from a cohort of PD patients and HC. Compared to HC, PD patients showed: (1) higher glutamine, serine, pyruvate and lower α-ketoglutarate levels (1H-NMR); (2) higher glycine and lower glutamic acid concentrations (UPLC/MS). Several pathways associated with amino acids, mitochondrial and antioxidant metabolism emerged as dysregulated in PD. Our findings highlight a prominent disruption of cellular bioenergetic pathways and amino acid homeostasis in PD.
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as part of standard practice. Patients meeting the criteria for early Alzheimer's disease will be considered for study participation, with the Investigator taking the additional inclusion/exclusion criteria into consideration. Up to 40 subjects will be enrolled. Subjects participating in the study will be randomized to receive either gummies containing L-Serine or placebo gummies, with the Investigator and study staff blinded to the group assignments.
Issues 전체보기
A study has found that consistently consuming ginseng (red ginseng) for five years or more can prevent cognitive decline caused by Alzheimer's disease.
A research team led by Professors Kim Ji-wook, Seo Kook-hee, and Choi Young-min of the Department of Psychiatry at Hallym University Dongtan Sacred Heart Hospital, and Professor Kim Hyun-soo of the Department of Laboratory Medicine, examined the association between ginseng and cognitive function and the modulation of apolipoprotein E4 (APOE4), a gene known as the Alzheimer's gene, in 160 elderly individuals aged 65 to 90 without dementia.
Ginseng intake was systematically assessed, including type, age of first consumption, duration, and frequency. A validated nutritional assessment method was also used to analyze dietary patterns based on protein, fruit, and vegetable types. Blood tests were also performed to determine the presence of apolipoprotein E4.
The results showed that most of the ginseng consumed was steamed and dried red ginseng, and that ginseng consumption was found to have a protective effect on episodic memory, a cognitive decline associated with early Alzheimer's disease. Episodic memory, also known as "episodic memory," refers to the memory of when and where an event occurred.
The protective effect was particularly pronounced in those who took ginseng for five years or more, or from middle age onward. However, the protective effect was diminished in those who carried the Alzheimer's disease gene, apolipoprotein E4.
A research team led by Professors Kim Ji-wook, Seo Kook-hee, and Choi Young-min of the Department of Psychiatry at Hallym University Dongtan Sacred Heart Hospital, and Professor Kim Hyun-soo of the Department of Laboratory Medicine, examined the association between ginseng and cognitive function and the modulation of apolipoprotein E4 (APOE4), a gene known as the Alzheimer's gene, in 160 elderly individuals aged 65 to 90 without dementia.
Ginseng intake was systematically assessed, including type, age of first consumption, duration, and frequency. A validated nutritional assessment method was also used to analyze dietary patterns based on protein, fruit, and vegetable types. Blood tests were also performed to determine the presence of apolipoprotein E4.
The results showed that most of the ginseng consumed was steamed and dried red ginseng, and that ginseng consumption was found to have a protective effect on episodic memory, a cognitive decline associated with early Alzheimer's disease. Episodic memory, also known as "episodic memory," refers to the memory of when and where an event occurred.
The protective effect was particularly pronounced in those who took ginseng for five years or more, or from middle age onward. However, the protective effect was diminished in those who carried the Alzheimer's disease gene, apolipoprotein E4.
Changes Experienced During the Clinical TrialThis clinical trial lasted for six months, with half of the participants receiving a placebo (fake medicine) and the other half taking the actual medicine.However, changes appeared immediately after taking the real medicine.📌 1) Initial Reaction – Increased Crying & Irritability (Heightened Alertness)Right after taking the real medicine for the first time, crying and irritability increased sharply.It was tough for about a month, but the research team explained that this is a phenomenon that can occur as a response to the medication.We were advised that 'things will gradually get better over time,' and indeed, after two weeks, we began to see signs of stabilization.📌 2) Remarkable Change – Improved Picky Eating & Language DevelopmentI had heard that Elserin could help with language development, but our child experienced an unexpected improvement in picky eating.Our child had difficulty accepting school meals, but→ after starting Elserin, they began eating the meals!Other children participating in the clinical trial also gave feedback that their eating habits had slightly changed.Additionally, it seemed that our child was speaking in full sentences more frequently.
